Three years after measles, mumps, and rubella revaccination in 38 human immunodeficiency virus-infected children who had achieved immune recovery after antiretroviral therapy, the prevalence of protective antibody levels was 85% for measles, 61% for mumps, and 79% for rubella, compared with 88%, 84%, and 100%, respectively, 1 month after revaccination.
cination among HIV-infected children receiving antiretroviral therapy and achieving immune recovery.
Patients, materials, and methods. This is a follow-up study of measles, mumps, and rubella revaccination among HIVinfected children receiving antiretroviral therapy. In brief, in October 2005, 51 HIV-infected children (mean age ‫ע‬ standard deviation [SD], 9.6 ‫ע‬ 2.8 years) with immune recovery after antiretroviral therapy (defined as a CD4 cell percentage 115% for 13 months) at Chiang Mai University Hospital (Chiang Mai, Thailand) were revaccinated with a single dose of the measles, mumps, and rubella vaccine Priorix (GlaxoSmithKline). The prevalence of protective antibody 1 month and 6 months after the revaccination were previously reported [4] . In the present study, these children were evaluated for the persistence of antibody levels 40 months after revaccination. The study protocol was approved by the research ethics committee of Chiang Mai University. Written informed consent was obtained from each child's parent or guardian before enrollment.
Blood samples collected from participants at each visit were handled according to the same set of standard operating procedures. In brief, they were sent to the specimen-processing unit р4 h after collection and were centrifuged. Plasma aliquots were then kept at -70ЊC until shipment. The specimens were tested 1-3 months after specimen collection. The tests were performed at the Department of Medical Sciences of the Thai Ministry of Public Health (Nonthaburi, Thailand). The enzyme-linked immunosorbent assay was performed using Enzygnost reagent (Dade Behring), with an internal quality control performed on each run. The optical density readings were interpreted as negative if !0.1, equivocal if 0.1-0.2, and positive if 10.2. The positive optical density readings for measles and rubella were then converted to enzyme-linked immunoassay units, as reported by Ratnam et al [5] . Antibody levels of у320 mIU/mL for measles [6] , 11:500 for mumps [7] , and у10 IU/ mL for rubella [8] were defined as protective antibody level. The most recent values of CD4 lymphocyte count and plasma HIV RNA level obtained within 3 months before or after the time of blood drawing were designated as current values. The mean decay of protective antibody at each time point (%) was determined by the following formula: ( ) Antibody titer at specific time Ϫ baseline antibody titer ϫ 100 . Baseline antibody titer Geometric mean titers were calculated with 95% confidence intervals for antibodies against each vaccine component at each follow-up time point. With respect to geometric mean titers, the mean of log-transformed titers was first obtained assuming that log-transformed titers were normally distributed with unknown variance. The 95% confidence intervals were then obtained by exponential transformation of the 95% confidence intervals for the mean of the log-transformed titers. SPSS software, version 16.0 (SPSS Inc), was used for statistical analysis. Comparisons of continuous variables were performed by the independent sample t test, and those of categorical variables were performed by the x 2 or Fisher exact test. Statistical significance was set at a 2-tailed P value !.05.
Results. Thirty-eight (75%) of 51 HIV-infected children who had been revaccinated with measles, mumps, and rubella in 2005 were studied in February 2009. These 38 children were approached to volunteer for a hepatitis A vaccine efficacy study because they did not have protective antibody to hepatitis in their 2005 baseline serum samples and were offered to co-enroll in the present study. The characteristics of the 13 children who did not participate were not different from the study group in terms of sex, age, CD4 cell percentage, and duration of antiretroviral therapy at the time of revaccination, but their baseline CD4 cell percentage was higher (mean ‫ע‬ SD, 8.2% ‫ע‬ 5.2% vs 4.1% ‫ע‬ 4.0%; P ! .01; data not shown). Table 1 presents the characteristics of the 38 children. Nineteen children (50%) were receiving nevirapine-based antiretroviral therapy, and the rest were receiving efavirenz-based antiretroviral therapy. Four children lived in an orphanage and were exposed to a measles outbreak in 2008, when they received additional doses of mea-sles vaccine as a part of the outbreak response [9] . None of the 38 children experienced any serious illness or needed hospitalization during the 40 months prior to this study.
Forty months after measles, mumps, and rubella revaccination, the prevalence of protective antibodies was 85% for measles, 61% for mumps, and 79% for rubella. The prevalence decreased significantly at month 40, compared with months 1 and 6, after revaccination for mumps and rubella, but not for measles (Table 2) . Of the 4 children who received additional second doses of measles vaccine during the measles outbreak in July 2008, all had protective antibody. At month 40, a total of 2 children who had been seropositive for measles at 6 months after revaccination became seronegative (the levels at month 6 were 888 and 3953 mIU/mL). Two other children who had no protective measles antibody at month 6 were found to have protective anti-measles antibody at month 40. Mumps antibody levels increased in 2 other children (from 1:190 to 1:599 in one child and from 1:142 to 1:712 in the other). No subject demonstrated an increase in rubella antibody levels.
The median annual decay rates for protective antibodies were Ϫ12.2% (interquartile range [IQR], Ϫ1.9% to Ϫ33.8%), Ϫ24.8% (IQR, Ϫ5.4% to Ϫ54.5%), and Ϫ16.4% (IQR, Ϫ2.2% to Ϫ23.9%) in the first 5 months after revaccination for measles, mumps, and rubella, respectively. The annual decay rate decreases in the subsequent month up to year 3. They were Ϫ2.7% (IQR, Ϫ1.2% to Ϫ4.6%), Ϫ3.6% (IQR, Ϫ0.5% to Ϫ6.2%), and Ϫ2.8% (IQR, Ϫ0.5% to Ϫ4.2%) for measles, mumps, and rubella, respectively.
Discussion. This study demonstrated the persistence of antibodies to measles, mumps, and rubella among HIV-infected children who achieved immune recovery after antiretroviral therapy for at least 40 months after revaccination. The prevalence of protective antibodies was 85% for measles, 61% for mumps, and 79% for rubella. There was a significant decrease in geometric mean titers over time, but the proportion of children with protective antibodies remained unchanged from 6 months to 40 months for measles.
Our study showed higher prevalence of protective antibody against measles after revaccination (85% at 40 months) versus those in 15 HIV-infected Swedish children (60% at 1 year) [10] and 18 HIV-infected American children (73% at 1 year) [11] . Although all children in these 3 studies were in immune recovery after having received antiretroviral therapy for a similar period of time (2-2.5 years), at the time of the study, 97% of our children were experiencing HIV suppression, compared with 51%-66% and 79% of children in the Swedish and US studies, respectively.
In our study the proportion of children with protective antibody to mumps slightly decreased from 66% to 61% three years after revaccination. These percentages are slightly lower than in the normal population, for which seropositivity to mumps is 74%-77% four to 20 years after vaccination [12, 13] .
We found that the percentage of children with protective antibody against rubella decreased from 90% at 6 months to 79% at 3 years after revaccination. The persistence of rubella antibody after measles, mumps, and rubella vaccination in the normal population is variable. Studies from Luxembourg and Finland revealed that 195% of vaccine recipients were still seropositive for rubella 7-20 years after vaccination [12, 14] , whereas a study of American children reported the decrease in seropositivity rate from 90% among 4-6-year-old children to 67% among 11-13-year-old children [15] . Although rubella is a rather mild disease, infection during pregnancy could lead to serious congenital anomalies. Proper counseling of older children and consideration of additional rubella vaccination when they reach adolescence may be warranted.
In conclusion, we have documented the persistence over a period of 3 years of measles, mumps, and rubella protective antibodies in HIV-infected children with immune recovery after antiretroviral therapy. From our data, it appears that revaccination of all HIV-infected children with measles, mumps, and rubella vaccine after immune recovery is indicated especially in countries with a high prevalence of measles. Nevertheless, only longer follow-up of revaccinated HIV-infected children could clarify how often the revaccination should be scheduled in these patients.
